Skip to main content

Diabetes Reversing Implants with enhanced Viability and long-term Efficacy

Objective

Diabetes mellitus is a chronic disease characterised by high blood glucose due to inadequate insulin production and/or insulin resistance which affects 382 million people worldwide. Pancreatic islet transplantation is an extremely promising cure for insulin-sensitive diabetes mellitus (ISDM), but side effects of lifelong systemic immunosuppressive therapy, short supply of donor islets and their poor survival and efficacy in the portal vein limit the application of the current clinical procedure to the most at-risk brittle Type I diabetes (T1D) sufferers. The DRIVE consortium will develop a novel suite of bio-interactive hydrogels (β-Gel) and on-demand drug release systems to deliver islets in a protective macrocapsule (β-Shell) to the peritoneum with targeted deposition using a specialised injection catheter (β-Cath). Pancreatic islets will be microencapsulated in β-Gels; biofunctionalised injectable hydrogels containing immunosuppressive agents and polymeric microparticles with tuneable degradation profiles for localised delivery of efficacy cues. These β-Gels will be housed in a porous retrievable macrocapsule, β-Shell, for added retention, engraftment, oxygenation, vascularisation and immunoprotection of the islets. A minimally invasive laparoscopic procedure (O-Fold) will be used to create an omental fold and at the same time deliver β-Shell. An extended residence time in β-Gel will enhance long-term clinical efficacy of the islets and result in improved glycemic control. The novel β-Gels will also be developed as human three-dimensional in-vitro models of in-vivo behaviour. Islet harvesting and preservation technologies will be developed to facilitate their optimised yield, safe handling and transport, and ease of storage. DRIVE will also enable the future treatment of a broader range of T1 and insulin-sensitive T2 diabetics by working with induced pluripotent stem cell experts to ensure the compatibility of our system with future stem cell sources of β-cells.

Field of science

  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /medical and health sciences/clinical medicine/transplantation
  • /medical and health sciences/clinical medicine/endocrinology/diabetes
  • /social sciences/social and economic geography/transport
  • /medical and health sciences/medical biotechnology/medical bioproducts/implants

Call for proposal

H2020-NMP-2014-two-stage
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

NATIONAL UNIVERSITY OF IRELAND GALWAY
Address
University Road
H91 Galway
Ireland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 435 576,11

Participants (14)

DUBLIN CITY UNIVERSITY
Ireland
EU contribution
€ 600 000
Address
Glasnevin
9 Dublin
Activity type
Higher or Secondary Education Establishments
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Germany
EU contribution
€ 679 153
Address
Geschwister-scholl-platz
72074 Tuebingen
Activity type
Higher or Secondary Education Establishments
UNIVERSITEIT UTRECHT
Netherlands
EU contribution
€ 498 555
Address
Heidelberglaan 8
3584 CS Utrecht
Activity type
Higher or Secondary Education Establishments
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Ireland
EU contribution
€ 700 496
Address
Belfield
4 Dublin
Activity type
Higher or Secondary Education Establishments
CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P.
Spain
EU contribution
€ 550 452,75
Address
Calle Monforte De Lemos 5
28029 Madrid
Activity type
Research Organisations
ABIEL SOCIETA A RESPONSABILITA LIMITATA
Italy
EU contribution
€ 887 366
Address
Viale Delle Scienze Sn
90128 Palermo
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CONTIPRO AS
Czechia
EU contribution
€ 600 625
Address
Dolni Dobrouc 401
561 02 Dolni Dobrouc
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EXPLORA SRL
Italy
EU contribution
€ 820 000
Address
Via Giacomo Peroni 386
00131 Roma
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INNOCORE TECHNOLOGIES BV
Netherlands
EU contribution
€ 600 812,50
Address
L.j. Zielstraweg 1
9713 GX Groningen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
BOSTON SCIENTIFIC LIMITED
Ireland
EU contribution
€ 715 020
Address
Ballybrit Business Park
H91 Galway
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INNOVA SRL
Italy
EU contribution
€ 273 000
Address
Via Cicerone, 66
00193 Roma
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
L'AZIENDA SOCIO SANITARIA TERRITORIALE (ASST) GRANDE OSPEDALE METROPOLITANO NIGUARDA
Italy
EU contribution
€ 79 750
Address
Piazza Ospedale Maggiore 3
20162 Milano
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
EU contribution
€ 579 113,75
Address
Wellington Square University Offices
OX1 2JD Oxford
Activity type
Higher or Secondary Education Establishments
ROYAL COLLEGE OF SURGEONS IN IRELAND
Ireland
EU contribution
€ 812 141,39
Address
Saint Stephen's Green 123
2 Dublin
Activity type
Higher or Secondary Education Establishments